Switch theme
Sign up to access all valuation multiples
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company’s portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson’s disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
1915
5.7K+
Last FY Revenue $3.3B
Last FY EBITDA $860M
$7.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Lundbeck achieved revenue of $3.3B and an EBITDA of $860M.
Lundbeck expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lundbeck valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $3.3B | XXX | XXX | XXX |
| Gross Profit | XXX | $2.7B | XXX | XXX | XXX |
| Gross Margin | XXX | 81% | XXX | XXX | XXX |
| EBITDA | XXX | $860M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 26% | XXX | XXX | XXX |
| EBIT | XXX | $492M | XXX | XXX | XXX |
| EBIT Margin | XXX | 15% | XXX | XXX | XXX |
| Net Profit | XXX | $473M | XXX | XXX | XXX |
| Net Margin | XXX | 14% | XXX | XXX | XXX |
| Net Debt | XXX | $1.7B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lundbeck's stock price is DKK 35 (or $5).
Lundbeck has current market cap of DKK 34.8B (or $5.2B), and EV of DKK 46.8B (or $7.1B).
See Lundbeck trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.1B | $5.2B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lundbeck has market cap of $5.2B and EV of $7.1B.
Lundbeck's trades at 2.1x EV/Revenue multiple, and 8.2x EV/EBITDA.
Equity research analysts estimate Lundbeck's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lundbeck's P/E ratio is not available.
See valuation multiples for Lundbeck and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.2B | XXX | $5.2B | XXX | XXX | XXX |
| EV (current) | $7.1B | XXX | $7.1B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 8.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 14.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 11.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 17.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLundbeck's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.4M for the same period.
Lundbeck's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lundbeck's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lundbeck and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 66% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lundbeck acquired XXX companies to date.
Last acquisition by Lundbeck was XXXXXXXX, XXXXX XXXXX XXXXXX . Lundbeck acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lundbeck founded? | Lundbeck was founded in 1915. |
| Where is Lundbeck headquartered? | Lundbeck is headquartered in Denmark. |
| How many employees does Lundbeck have? | As of today, Lundbeck has 5.7K+ employees. |
| Who is the CEO of Lundbeck? | Lundbeck's CEO is Mr. Charl van Zyl. |
| Is Lundbeck publicy listed? | Yes, Lundbeck is a public company listed on CSE. |
| What is the stock symbol of Lundbeck? | Lundbeck trades under HLUN A ticker. |
| When did Lundbeck go public? | Lundbeck went public in 2022. |
| Who are competitors of Lundbeck? | Similar companies to Lundbeck include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Lundbeck? | Lundbeck's current market cap is $5.2B |
| Is Lundbeck profitable? | Yes, Lundbeck is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
